Navigation Links
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
Date:3/7/2013

nagement Comment"WuXi is succeeding on three fronts: growing, investing to sustain our growth, and returning capital to shareholders," said Dr. Ge Li, Chairman and Chief Executive Officer.  "We achieved strong double-digit revenue growth in the fourth quarter and full year of 2012.  We also achieved double-digit growth in earnings per ADS in 2012.  We continued to invest to build capabilities and capacity in order to sustain revenue and earnings growth for the long term.  While growing and investing, we generated strong free cash flow that allowed us to purchase our shares.

"I am proud of what we accomplished in 2012," Dr. Li continued.  "Revenue growth of 22.8% to about $500 million was driven by continuing growth in demand for WuXi's services in all of our businesses.  In February, we opened a chemistry facility in Wuhan to give our customers a new pricing option.  In October, we began operation of a new cGMP drug-substance biologics manufacturing facility in Wuxi.  We signed many new contracts in biologics, including a joint venture with MedImmune to co-develop their anti-IL6 monoclonal antibody for the China market. We delivered nine small molecule preclinical drug candidates for our clients.  We produced advanced intermediates for five commercial products and grew our late-stage manufacturing pipeline.  The company entered into an agreement to form a joint venture with PRA to offer clinical research services in China.  We purchased 7% of our ADSs outstanding at the beginning of the year.  WuXi achieved year-over-year growth in GAAP diluted EPS of 10.8% and in non-GAAP diluted EPS of 13.3%.  And we continued to invest in building new capabilities and capacities with $67.8 million in new capital assets, to drive future revenue and income growth.

"2013 looks to be another good year.  We expect 13-15% revenue growth, driven by increasing demand across our service offerings.  In
'/>"/>

SOURCE Wuxi PharmaTech Co. Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
2. WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
3. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
4. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
5. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
6. WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat(TM) Antibody Collaboration
7. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
8. WuXi PharmaTech Receives GLP Certificate from SFDA for Suzhou Toxicology Facility
9. WuXi PharmaTech Announces Second-Quarter 2012 Results
10. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
11. WuXi PharmaTech Announces First-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has ... - Global Industry Analysis, Size, Share, Growth, Trends And ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... on patients in order to treat dental impairments, for ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... Radiologist Delivers Chemo Drug Directly to Eye via,Ophthalmic ... interventional,radiology treatment successfully treats advanced retinoblastoma -- a,deadly, ... children -- and often,spares them from having their ... a study released today at the Society of,Interventional ...
... Dependent on Outcomes of New Analyses or Confirmatory ... for Tuesday March 18, 2008, BERKELEY HEIGHTS, ... ) announced that the Food and Drug,Administration,s (FDA) ... that available data are not adequate to support ...
Cached Medicine Technology:New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 2New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 3New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 4FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 2FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 3FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 4FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 5FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 6
(Date:4/23/2014)... for-profit and non-profit organizations in Washington will receive ... Concept grants to accelerate maturation of promising health-related ... Sciences Discovery Fund (LSDF) announced today. Also announced ... the Washington Biotechnology & Biomedical Association (WBBA) to ... next generation of entrepreneurs and help early-stage companies ...
(Date:4/23/2014)... R.I. Parents and physicians concerned about an increase ... marijuana can breathe a sigh of relief. According to ... 20 years worth of data from states with and ... lead to increased use among adolescents. The study is ... Journal of Adolescent Health . , "Any time ...
(Date:4/23/2014)... The research, published in the journal Oncotarget ... have different appearances or their own DNA signatures ... it difficult to design effective, targeted treatment strategies. ... the EGFR mutation and either the KRAS or ... driven by the EGFR gene mutation have that ...
(Date:4/23/2014)... that proliferation of endogenous neural precursor cells cannot ... axons. From the perspective of neural plasticity, Dr. ... in China observed the effects of functional electrical ... and expression of basic fibroblast growth factor and ... the infarct side. The researchers found that functional ...
(Date:4/22/2014)... popular high school sport in the United States with ... researchers in the Center for Injury Research and Policy ... and describe the occurrence and distribution patterns of basketball-related ... athletic training setting among adolescents and teens. , The ... Training , examined data relating to adolescents 13-19 years ...
Breaking Medicine News(10 mins):Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3
... the nation,s largest builder of healthcare facilities, has ... hospital for Virtua Health. Turner is serving as ... scheduled for completion in 2011. The 690,000-sq.-ft. hospital ... quality clinical services and patient safety, an assurance ...
... 30 Diagnosoft, Inc., an innovator in magnetic ... diagnosis, staging and therapeutic monitoring of cardiovascular disease, ... Strain-encoding, or SENC, is a new MRI ... contraction, or relaxation, of the heart,s myocardium. ...
... Healthcare Management Group, Inc. (Phyhealth) (Pink Sheets: PHYH), ... in partnership with physicians and manager of Physhield ... released the following letter to its shareholders:Dear Phyhealth ... Congress and a new administration in Washington. ...
... Study says initiatives should target both coverage and access to ... Children who do not have health insurance and no regular ... unmet medical needs, researchers at the University of Michigan C.S. ... government needs to do more to safeguard the health of ...
... (Nasdaq: BCRX ) today announced that its fourth ... on Friday, February 6, 2009. Following the release, BioCryst will ... Eastern Time to discuss the financial results and provide an ... by Jon P. Stonehouse, President and Chief Executive Officer, Stuart ...
... Neurosilicon,s novel Photoconductive Stimulation Device (PSD) was highlighted in ... Astrocytic Ca2+ Waves Guide CNS Growth Cones to Remote ... November 2008 issue of The Public Library of Science ... in mediating axonal guidance. It is known that the ...
Cached Medicine News:Health News:Turner Reaches Milestone on $323 Million Virtua West Jersey Replacement Hospital in Voorhees, N.J. 2Health News:Diagnosoft(R) Introduces Its Third MRI Analysis Innovation 2Health News:Phyhealth Provides Update to Shareholders 2Health News:Phyhealth Provides Update to Shareholders 3Health News:Phyhealth Provides Update to Shareholders 4Health News:Medical Needs of 6.2 Million U.S. Kids Go Unmet 2Health News:BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009 2Health News:BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009 3Health News:Novel Photoconductive Cellular Depolarization Technology Reveals Insight Into Neuronal Growth, Guidance, and Regeneration 2
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... Medicine POLYSORB Meniscal Stapler XLS consists of ... legs of the staple. The staple is ... the meniscus. The staple is made of ... lactic acid and glycolic acids. Polylactic/polyglycolic acid ...
Medicine Products: